Methotrexate (MTX) is recognized as the anchor drug in the algorithm treating chronic arthritis (RA, psoriatic arthritis), as well as a steroid sparing agent in other inflammatory conditions (polymyalgia rheumatica, vasculitis, scleroderma). Its main mechanism of action has been related to the increase in extracellular adenosine, which leads to the effects of A2 A receptor in M1 macrophages that dampens TNF and IL12 production and increases IL1Ra and TNFRp75. By acting on A2 B receptor on M2 macrophages it enhances IL10 synthesis and inhibits NF-kB signaling.
MTX is now the best first-line treatment in all the recommendations by the Scientific Societies and has a retention rate at 2 years of more than 60% both in RA and in PsA, associated with an Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; b-DMARD, biological synthetic disease modified antirheumatic drugs; cs-DMARD, conventional synthetic disease modified antirheumatic drugs; DHFR, dihydrofolate reductase; ET, essential thrombocythemia; GPI, glucose-6-phosphate isomerase; IL6R, IL6 receptor; MTX, methotrexate; PsA, psoriatic arthritis; PV, policythemia vera; TCZ, tocilizumab; ts-DMARDs, targeted synthetic DMARDs.
Intracellular and extracellular mechanisms of action of MTX
Being a chemotherapy agent, MTX acts as a folate antagonist that inhibits dihydrofolate reductase (DHFR) and ultimately purine synthesis, blocking highly replicative cells in the S phase. These effects can be bypassed and the clinical effects blocked by folinic acid supplementation acting on the folate pathway downstream of DHFR and relieving the inhibition of purine synthesis. However, at the lower doses used in RA, folinic acid reduces the side effects associated with MTX treatment without reverting its anti-inflammatory and immune-suppressive actions but maintaining its clinical efficacy, proving that other mechanisms of action are responsible for its DMARD activity. In addition, MTX blocks the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) that converts 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to formyl-AICAR (FAICAR).
AICAR leads to enhanced release of adenine nucleotides into the extracellular space and converted to adenosine, which is thought to be the major driver of the pharmacologic action of MTX in RA. 10, 11 Adenosine inhibits oxygen radical by neutrophils, suppresses monocyte-derived cytokine/chemokine (among which TNF-and IL12) production acting on A2 A , and through A2 B AR increases IL10 production and promotes M2 macrophage activation. 12 These pharmacobiologic effects may explain why the combination therapy of MTX + anti-TNF is more effective than MTX alone or anti-TNF alone. 5 Moreover, rituximab (RTX) and abatacept (CTLA4-Ig) led to a better ACR 50 response or Boolean remission rate compared to MTX alone, yet it did not reach statistical significance, 13, 14 whereas in RA, only TCZ monotherapy showed to be clearly superior to MTX monotherapy. 15 
MTX AND CYTOKINE SYNTHESIS
The histopathological analysis of synovial tissue inflammation in RA has shown that RA synovitis can be roughly divided into at least three major groups, myeloid, lymphoid, and fibroid pathotypes, respectively.
If after MTX therapy the synovial inflammation still persists, the first subset responds better to TNF-I and the second to IL6-R inhibition. 16 Why does not IL6 inhibition receives any additive effect by MTX?
In Jurkat cells stimulated with TNF, MTX suppressed NF-kB activation by inhibiting IkB degradation and suppressing IkB phosphorylation, effects all determined by adenosine. 17 MTX leads to the downregulation of TNF and IL1 and to an increase of IL1Ra and TNFRp75. 18 It also inhibits NF-kB activity in T cells, via BH4 depletion, and reduces activation of JNK, p53, and NF-kB activity in fibroblastlike synoviocytes through the release of adenosine and adenosine receptor activation, normalizing in vivo elevated NF-kB activity. 19 In addition to these effects, in collagen-induced arthritis, Neurath et al. demonstrated that intraperitoneal MTX injection, prior to the development of arthritis, significantly suppressed IL15-induced synthesis in splenic mononuclear cells of TNF, indirectly. However, no significant effects were seen on IL6. 20 In the glucose-6-phosphate isomerase-induced (GPI) model of arthritis, MTX inhibits GPI-induced arthritis, with a vanishing effect, showing its ability to significantly reduce IL6 and IL6 receptor (IL6R) expression. Nevertheless this effect was mirrored by the progressive decrease of SLC19A1 expression, which is an important folate carrier for MTX intracellular uptake ( Fig. 1A) . When SCL19A1 expression decreases, MTX does not exert its effects anymore. Therefore, IL6 is the major driver of MTX unresponsiveness in the GPI model of arthritis. 21 MTX exerts its suppression on cytokines promoting the release of adenosine producing its modulatory effect on inflammatory signals through A2 A and A2 B receptors on macrophages leading to the suppression of proinflammatory cytokines release (i.e., TNF-) and
promotion of anti-inflammatory molecules (i.e., IL-10) ( Fig. 1B ). 22 Moreover, MTX was demonstrated to repress the inflammatory signal in RA due to its inhibitory effect on another proinflammatory mediator,
as High-mobility group box 1 (HMGB1). In particular, MTX interferes with HMGB1 and RAGE ligand, at molecular level, acting via JAK/STAT pathway with a repression of TNF-overproduction. 23 
MTX, TNF-I, AND TOCILIZUMAB IN CLINICAL TRIALS
In all clinical trials, including TNF inhibitors (i.e., infliximab, adalimumab, golimumab, certolizumab, and etanercept), the rate of ACR50 or DAS-remission achievement was not statistically different when comparing patients treated with monoclonals alone and MTX alone.
On the other hand, the combination of b-DMARD and MTX, was associated with a significant reduction in joint damage compared to MTX alone and in MTX naive patients only. 31 Considering mechanisms of action other than TNF inhibition, only TCZ proved to be clearly superior to MTX. 9 Therefore, we hypothesize that MTX has similar efficacy to anti-TNF monotherapy through Adenosine and JAKs inhibition. However, selective JAK inhibition does not directly suppress TNF synthesis by immune cells. 32 Therefore, the additive role of MTX, when used in combination with TNF inhibitors, may be supported in vivo in RA by the MTX suppressive effects on IL1 , IL3, IL5, IFN , and as expected from the JAK1 inhibition, also on IL6. 33 In clinical trials, TCZ was demonstrated to be superior to MTX, and to be more successful in RA patients who are incomplete responders to TNF inhibition. 9 In fact, IL6 signaling through IL6-IL6R-gp130 binding, leads to JAK1/JAK2/STAT3 activation. 32 Therefore, TCZ acting upstream of JAKs and blocking the interaction of IL6 with its receptors, can more strongly suppress the inflammatory signal and once MTX is added, acting downstream, limited additional effects are registered. These insights may allow to understand why TCZ appears to be the only b-DMARD superior to MTX alone. 34 
JAK INHIBITORS AND MTX
The inhibition of JAK-STAT phosphorylation has been tested in
Drosophila as a cell model to screen small molecules, as well as in several immune cells, like splenocytes, T lymphocytes, and whole blood or directly on enzyme assays. [35] [36] [37] [38] When JAK inhibitors are tested, TYK2 are expressed ubiquitously. 37 For this reason, JAK3 inhibition appeared to be a first rational target in rheumatic inflammatory diseases. The randomized clinical trial comparing tofacitinib and MTX showed a higher effectiveness of tofacitinib at 5 and 10 mg compared to MTX at 10-20 mg/week, 6 suggesting that specific inhibition of JAK1/JAK3, by tofacitinib, appears to be superior to MTX, which acts by inhibiting JAK1/JAK2.
When used in combination, MTX plus tofacitinib showed similar clinical effect to MTX plus adalimumab, 41 suggesting that the specific inhibition led by tofacitinib combined with JAK1/JAK2 inhibition by MTX may have additive effects. The same results did not occur with baricitinib, which acts on JAK1/JAK2. In fact, clinical trial showed that the addition of MTX to baricitinib does not result in significantly better clinical benefits, already obtained by baricitinib alone, which can rescue MTX incomplete responders owing to its specific inhibition, though the combination led to a better control of erosions. 42 Finally, given the different JAK targets being inhibited, it can be hypothesized that the combination of baricitinib plus LFN might be of clinical interest considering that LFN inhibits JAK3 and this may explain also the additive effect of LFN when used in combination with MTX. 43 The same should occur with Upadacitinib and Filgotinib. 44, 45 When examining the side effects associated to JAK inhibitors, the major one is represented by the occurrence of Herpes Zoster infection. 46 Despite discordant results have been described in the literature, 47 yet most recent data suggest that Zoster infection may be a side effect of MTX therapy. 48 All these data suggest that MTX may indeed display JAK1/JAK2 inhibition in vivo.
PERSPECTIVES
MTX is a fundamental part of the therapeutic strategy in several inflammatory and autoimmune diseases. Its efficacy is recognized as a fundamental first step approach in several inflammatory diseases.
Its effects on the purinergic pathways through adenosine modulation and on NF-kB signal together with emerging insights into its action on JAK1/JAK2 pathways (Fig. 2) suggest that it will certainly remain the anchor drug of excellence in the clinics.
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